Charles River Laboratories stock (US1591881009): Zacks trims Q2 2026 EPS estimate while shares rebound on NYSE

Charles River Laboratories shares traded higher on the New York Stock Exchange on Friday, even as Zacks Research pared back its forecast for the company’s upcoming Q2 2026 earnings per share, highlighting shifting expectations around the US contract research group’s profit trajectory.

According to a Zacks Research note dated 05/29/2026, the analyst team now expects Charles River Laboratories to earn USD 2.72 per share in Q2 2026, down from a prior estimate of USD 2.85 per share for the same period, while maintaining an outlook for longer-term earnings growth.MarketBeat citing Zacks Research as of 05/29/2026

The same report notes that the consensus estimate for the company’s full-year 2026 earnings stands at USD 11.05 per share as of 05/29/2026, providing a reference point for how the updated quarterly projection fits into the broader earnings path.MarketBeat citing Zacks Research as of 05/29/2026

On the home US market, Charles River Laboratories International (ticker: CRL) last closed at USD 181.41 on the NYSE on 05/29/2026, up 10.28% on the day, according to price data compiled by MarketBeat.MarketBeat as of 05/29/2026

MarketBeat data indicate that the stock was trading at USD 199.62 at the start of 2026 and has since declined by about 9.1% to the latest level of USD 181.41 as of 05/29/2026, underscoring how the recent move still leaves the share price below its early-year mark.MarketBeat as of 05/29/2026

For investors following the stock from Germany, Charles River Laboratories is also available via secondary trading venues such as Tradegate, where prices are typically quoted in euro and track the primary NYSE listing, though liquidity is lower than in the United States.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

Charles River Laboratories: core business model

Charles River Laboratories focuses on providing outsourced preclinical research, safety assessment, and manufacturing-related services that help pharmaceutical, biotechnology, and academic customers accelerate drug development and biologics production.

Valuation metrics and multiples for Charles River Laboratories

With a closing price of USD 181.41 on the NYSE on 05/29/2026, market data providers such as MarketBeat estimate the company’s market capitalization in the mid-teens billions of US dollars, reflecting investor expectations for continued demand for its contract research services.

Based on the consensus full-year 2026 EPS estimate of USD 11.05 per share reported alongside the Zacks Research update on 05/29/2026, the stock is trading on a forward price-earnings multiple in the mid-teens range, giving a rough indication of how the market is valuing its earnings power relative to peers in the broader life-sciences tools and services segment.

Conclusion

The combination of a higher NYSE share price on 05/29/2026 and a reduced Q2 2026 EPS estimate from Zacks Research underscores how sentiment toward Charles River Laboratories is being shaped simultaneously by market momentum and more cautious near-term earnings assumptions.

At the same time, valuation indicators derived from the latest consensus figures suggest that investors continue to assign a mid-teens forward earnings multiple to the stock, reflecting expectations that the company’s role in outsourced preclinical and manufacturing services will support its longer-term earnings profile even amid quarter-to-quarter estimate revisions.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.